The Medicines Patent Pool welcomes decision EB156(29) on the incorporation of World Prematurity Day into the WHO calendar to raise awareness and promote strengthened approaches for preventing preterm births and treating and caring for preterm infants. Among conditions that affect preterm infants severely, with a particularly wide equity gap between high-income countries and low- and middle-income countries, are complications and mortality from respiratory syncytial virus (RSV) infection. But there are good news, as game-changing monoclonal antibodies can prevent most of these unnecessary infant deaths.

There is now an opportunity to ensure broad access to these game-changing innovations. This is where MPP can help, in partnerships with originator pharmaceutical companies, biosimilar manufacturers, governments, and public health organizations, including partners of the Global Accelerator for Paediatric Formulations. Let’s work together!